The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG). MiMedx is a Georgia-based developer, manufacturer, and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membranes. The Firm’s investigation concerns the Company’s September 4, 2013, announcement that was in receipt of an "Untitled Letter" from the Food and Drug Administration ("FDA"). The letter stated MiMedx's Surgical Biologics unit violated the Public Health Service Act by unlawfully manufacturing drugs at one of its plants, and thereby marketed unapproved biologics products. On this news, shares of MiMedx fell $2.21 per share to more than 36.49% to close at $3.85 on September 4, 2013. If you currently own MiMedx common stock and are interested in discussing your rights as a shareholder, or have information relating to this investigation, please contact Kip B. Shuman or Rusty E. Glenn toll free at (866) 974-8626 or email Mr. Shuman at firstname.lastname@example.org or email Mr. Glenn at email@example.com. The Shuman Law Firm represents investors throughout the nation, concentrating its practice in stockholder litigation.